CA2250067A1 - Dosage in vitro a polarisation de fluorescence - Google Patents

Dosage in vitro a polarisation de fluorescence Download PDF

Info

Publication number
CA2250067A1
CA2250067A1 CA 2250067 CA2250067A CA2250067A1 CA 2250067 A1 CA2250067 A1 CA 2250067A1 CA 2250067 CA2250067 CA 2250067 CA 2250067 A CA2250067 A CA 2250067A CA 2250067 A1 CA2250067 A1 CA 2250067A1
Authority
CA
Canada
Prior art keywords
protein
domains
proteins
test substance
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2250067
Other languages
English (en)
Inventor
Berkley A. Lynch
Ian A. Macneil
Mark J. Zoller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ariad Pharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2250067A1 publication Critical patent/CA2250067A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne un procédé de dosage in vitro permettant d'identifier une substance test qui inhibe l'association mutuelle d'une paire de protéines. Ce procédé consiste à produire une paire de protéines aptes à s'associer, l'une des protéins étant porteuse d'une substande fluorescente liée de manière covalente; à préparer un mélange contenant les deux protéins et au moins une substance test; à irradier le mélange avec de la lumière polarisée d'une longueur d'onde appropriée permettant l'excitation de la substance fluorescente telle que l'indique l'émission de lumière polarisée; à mesurer le degré de polarisation de l'émission et à déterminer l'effet dû à la présence ou à la concentration de la substance test en réduisant la polarisation de l'émission observée d'un mélange de deux protéines seules. L'activité inhibitrice de la substance test est en corrélation avec les valeurs réduites de dépolarisation.
CA 2250067 1996-04-18 1997-04-18 Dosage in vitro a polarisation de fluorescence Abandoned CA2250067A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1559096P 1996-04-18 1996-04-18
US60/015,590 1996-04-18
US2987096P 1996-11-06 1996-11-06
US60/029,870 1996-11-06

Publications (1)

Publication Number Publication Date
CA2250067A1 true CA2250067A1 (fr) 1997-10-23

Family

ID=26687596

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2250067 Abandoned CA2250067A1 (fr) 1996-04-18 1997-04-18 Dosage in vitro a polarisation de fluorescence

Country Status (5)

Country Link
EP (1) EP0898709A2 (fr)
JP (1) JP2000512737A (fr)
AU (1) AU727108B2 (fr)
CA (1) CA2250067A1 (fr)
WO (1) WO1997039326A2 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998018956A1 (fr) * 1996-10-28 1998-05-07 Panvera Corporation Mesure de l'activite de la kinase par polarisation de fluorescence
US7105307B2 (en) 1997-08-30 2006-09-12 Cyclacel, Ltd. Compositions and methods for screening for modulators of enzymatic activity
ATE317122T1 (de) * 1997-09-05 2006-02-15 Matsushita Electric Ind Co Ltd Fluoreszierende polarisation
GB9923208D0 (en) * 1999-10-01 1999-12-08 Cambridge Drug Discovery Ltd Assay
MY140679A (en) 2001-05-24 2010-01-15 Avanir Pharmaceuticals Inhibitors of macrohage migration inhibitory factor and methods for identifying the same
EP1402263B1 (fr) * 2001-07-02 2009-10-28 Arctic Diagnostics OY Colorants de difluorure dipyrromethenebore absorbant deux photons et leurs applications
ATE339475T1 (de) 2001-07-02 2006-10-15 Arctic Diagnostics Oy Verfahren zur hydrophilierung von fluoreszierenden markierstoffen
TW200418829A (en) 2003-02-14 2004-10-01 Avanir Pharmaceutics Inhibitors of macrophage migration inhibitory factor and methods for identifying the same
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
AU2004268941A1 (en) 2003-08-22 2005-03-10 Avanir Pharmaceuticals Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
WO2005089454A2 (fr) * 2004-03-18 2005-09-29 Transtech Pharma, Inc. Analyse par polarisation de fluorescence
US7608407B2 (en) * 2004-11-16 2009-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Fluorescence polarization assay for determining histidine decarboxylase activity
AU2006227297A1 (en) 2005-03-24 2006-09-28 Avanir Pharmaceuticals Thienopyridinone derivatives as macrophage migration inhibitory factor inhibitors
US9164086B2 (en) 2011-10-18 2015-10-20 Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. Fluorescent dyes with phosphorylated hydroxymethyl groups and their use in light microscopy and imaging techniques
EP2944958A1 (fr) 2014-04-04 2015-11-18 Techno-Path (Distribution) Procédé de prédiction d'instabilité phénotypique dans une cellule
JP6629830B2 (ja) * 2014-07-15 2020-01-15 バリタセル リミテッド 試料中の抗体濃度を測定する方法
EP3075844A1 (fr) 2015-04-01 2016-10-05 Valitacell Limited Procédé de détermination d'une caractéristique fonctionnelle ou de composition d'un milieu de culture cellulaire

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257774A (en) * 1979-07-16 1981-03-24 Meloy Laboratories, Inc. Intercalation inhibition assay for compounds that interact with DNA or RNA
DE4009848A1 (de) * 1990-03-27 1991-10-02 Boehringer Mannheim Gmbh Verfahren zum nachweis von phosphoryliertes tyrosin enthaltenden proteinen
WO1993003377A1 (fr) * 1991-07-31 1993-02-18 Ziltener Hermann J Procede de detection de restes de phosphotyrosine
CA2054602C (fr) * 1991-10-31 2003-04-22 Anthony Pawson Methode de dosage d'une substance influant sur un systeme de regulation d'un ligand phosphoryle-sh2
WO1997010253A1 (fr) * 1995-09-15 1997-03-20 Merck & Co., Inc. Dosage a rendement eleve utilisant des proteines hybrides

Also Published As

Publication number Publication date
AU2807697A (en) 1997-11-07
AU727108B2 (en) 2000-11-30
WO1997039326A2 (fr) 1997-10-23
JP2000512737A (ja) 2000-09-26
EP0898709A2 (fr) 1999-03-03
WO1997039326A3 (fr) 1997-12-24

Similar Documents

Publication Publication Date Title
US6207397B1 (en) In vitro fluorescence polarization assay
AU727108B2 (en) In vitro fluorescence polarization assay
US5763571A (en) Inhibiting protein interactions
US7341845B2 (en) Method for identifying kinesin inhibitors
US5693476A (en) Methods of screening for compounds capable of modulating vesicular release
JP2004523726A (ja) コンフォメーションに敏感な結合ペプチドの同定方法およびその利用
US8399201B2 (en) Polypeptide complex of TRPM8 and calmodulin and its uses thereof
EP2241619A1 (fr) Développement de kinases étiquetées P-loop à fluorescence pour le criblage des inhibiteurs
Moll et al. Biomolecular interaction analysis in functional proteomics
WO1996021011A9 (fr) PEPTIDES SPECIFIQUES DU PREMIER DOMAINE SH-3 DE Crk
US20040072319A1 (en) Molecules that modulate ubiquintin-dependent proteolysis and methods for identifying same
US20070231835A1 (en) Proteomic Screening for Redox State Dependent Protein-Protein Interactions
WO1996021011A2 (fr) PEPTIDES SPECIFIQUES DU PREMIER DOMAINE SH-3 DE Crk
WO2003059943A2 (fr) Peptides specifiques a la conformation, de liaison de la proteine kinase, procedes et produits associes
US20230374088A1 (en) PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF Kif7
US20030104423A1 (en) Sigma binding region of RNA polymerase and uses thereof
KR100888805B1 (ko) 특정 아미노산이 표지된 단백질과 1ｄ ｎｍｒ 기법을이용하여 단백질의 활성 부위에 결합하는 화합물을검색하는 방법
KR100456054B1 (ko) 특정 아미노산이 표지된 단백질과 2ｄ ｎｍｒ 기법을이용하여 단백질의 활성 부위에 결합하는 화합물을검색하는 방법
US7267959B2 (en) Drug target within the sulfonylurea receptor
Gril et al. Affinity chromatography for purification of the modular protein growth factor receptor-bound protein 2 and development of a screening test for growth factor receptor-bound protein 2 Src homology 3 domain inhibitor using peroxidase-linked ligand
Hayes Chemical inhibitors of protein-protein interactions involved in G protein-mediated signaling events as potential therapeutics
JP2003185655A (ja) プロリンリッチなペプチドとｓｈ３ドメイン含有ペプチドとの相互作用を阻害する化合物のスクリーニング法

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead